We have also investigated the participation of signalling pathways, such as NLRP3, MAPK, PKC, and NF-κB, as well as the existing diagnostic tools and therapeutic treatments for the management of DCM. This evidence concerns the gene PRRT2 and familial dilated cardiomyopathy.